[HTML][HTML] A detailed evaluation of the effect of prostate-specific antigen–based screening on morbidity and mortality of prostate cancer: 21-year follow-up results of the …
II de Vos, A Meertens, R Hogenhout, S Remmers… - European Urology, 2023 - Elsevier
Background Considering the long natural history of prostate cancer (PCa), long-term results
of the European Randomised Study of Screening for PCa (ERSPC) are crucial. Objective To …
of the European Randomised Study of Screening for PCa (ERSPC) are crucial. Objective To …
Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit
PJ Van Leeuwen, D Connolly, A Gavin… - European Journal of …, 2010 - Elsevier
BACKGROUND: To estimate the benefits of prostate-specific antigen (PSA) screening on
prostate cancer (Pca) metastasis and Pca-specific mortality, we compared two populations …
prostate cancer (Pca) metastasis and Pca-specific mortality, we compared two populations …
Screening for prostate cancer: results of the Rotterdam section of the European randomized study of screening for prostate cancer
MJ Roobol, R Kranse, CH Bangma, AG van Leenders… - European urology, 2013 - Elsevier
Background Evidence from randomized trials on the effects of screening for prostate cancer
(PCa) on disease-specific mortality accumulates slowly with increasing follow-up. Objective …
(PCa) on disease-specific mortality accumulates slowly with increasing follow-up. Objective …
A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer
J Hugosson, MJ Roobol, M Månsson, TLJ Tammela… - European urology, 2019 - Elsevier
Abstract Background The European Randomized study of Screening for Prostate Cancer
(ERSPC) has previously demonstrated that prostate-specific antigen (PSA) screening …
(ERSPC) has previously demonstrated that prostate-specific antigen (PSA) screening …
Metastatic prostate cancer incidence and prostate-specific antigen testing: new insights from the European Randomized Study of Screening for Prostate Cancer
Abstract Background The European Randomized Study of Screening for Prostate Cancer
(ERSPC) has shown a 21% reduction in prostate cancer (PCa) mortality and a 1.6-fold …
(ERSPC) has shown a 21% reduction in prostate cancer (PCa) mortality and a 1.6-fold …
Prostate-cancer mortality at 11 years of follow-up
FH Schröder, J Hugosson, MJ Roobol… - … England Journal of …, 2012 - Mass Medical Soc
Background Several trials evaluating the effect of prostate-specific antigen (PSA) testing on
prostate-cancer mortality have shown conflicting results. We updated prostate-cancer …
prostate-cancer mortality have shown conflicting results. We updated prostate-cancer …
Prostate cancer mortality in the Finnish randomized screening trial
TP Kilpeläinen, TL Tammela, N Malila… - Journal of the …, 2013 - academic.oup.com
Background Prostate cancer (PC) screening with prostate-specific antigen (PSA) has been
shown to decrease PC mortality by the European Randomized Study of Screening for …
shown to decrease PC mortality by the European Randomized Study of Screening for …
The Finnish prostate cancer screening trial: analyses on the screening failures
TP Kilpeläinen, TLJ Tammela, N Malila… - … Journal of Cancer, 2015 - Wiley Online Library
Prostate cancer (PC) screening with prostate‐specific antigen (PSA) has been shown to
decrease PC mortality in the European Randomized Study of Screening for Prostate Cancer …
decrease PC mortality in the European Randomized Study of Screening for Prostate Cancer …
[HTML][HTML] Relationship between baseline prostate-specific antigen on cancer detection and prostate cancer death: long-term follow-up from the European randomized …
S Remmers, CH Bangma, RA Godtman, SV Carlsson… - European urology, 2023 - Elsevier
Abstract Background The European Association of Urology guidelines recommend a risk-
based strategy for prostate cancer screening based on the first prostate-specific antigen …
based strategy for prostate cancer screening based on the first prostate-specific antigen …
Prostate cancer mortality reduction by prostate-specific antigen–based screening adjusted for nonattendance and contamination in the European Randomised Study …
BACKGROUND: Prostate-specific antigen (PSA) based screening for prostate cancer (PCa)
has been shown to reduce prostate specific mortality by 20% in an intention to screen (ITS) …
has been shown to reduce prostate specific mortality by 20% in an intention to screen (ITS) …